达格列净在慢性肾脏病中的长期效应:一项时间-事件分析
本研究基于DAPA-CKD试验的患者水平数据,构建闭环队列水平分区生存模型,预测达格列净对关键肾脏终点的时间-事件影响,并与DECLARE-TIMI 58试验的亚组人群合并进行平行生存分析。结果显示,在DAPA-CKD人群中,达格列净预计将进展至肾衰竭的时间延缓6.6年,合并CKD人群结果相似,延缓6.3年。
要点
- 达格列净可延迟肾衰竭、全因死亡、肾功能持续下降和心衰住院的发生时间。
- 在DAPA-CKD人群中,达格列净预计将肾衰竭时间延缓6.6年。
- 在合并CKD人群中,达格列净预计将肾衰竭时间延缓6.3年。
核心结论
- 在终生时间范围内,达格列净可能显著延迟慢性肾脏病患者不良临床结局的平均发生时间,包括进展风险中等者。
研究设计与样本
- 基于DAPA-CKD试验患者水平数据,参数化闭环队列水平分区生存模型,预测关键试验终点的时间-事件。
- 将DAPA-CKD数据与DECLARE-TIMI 58试验亚组人群合并,形成涵盖不同CKD分期的合并CKD人群,并进行平行生存分析。
主要发现
- 在DAPA-CKD和合并CKD人群中,达格列净延迟肾衰竭、全因死亡、肾功能持续下降和心衰住院的首次事件时间。
- 在DAPA-CKD人群中,达格列净预计将肾衰竭时间延缓6.6年(达格列净:25.2,95%CI 19.0-31.5;标准治疗:18.5,95%CI 14.7-23.4)。
- 在合并CKD人群中,达格列净预计将肾衰竭时间延缓6.3年(达格列净:36.0,95%CI 31.9-38.3;标准治疗:29.6,95%CI 25.5-34.7)。
临床怎么用
- 对于慢性肾脏病患者,达格列净治疗可能长期延缓肾衰竭进展,支持临床决策中考虑其长期获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial demonstrated that patients with or without type 2 diabetes who were treated with dapagliflozin experienced slower progression of CKD versus those receiving placebo. Understanding the effect of long-term treatment with dapagliflozin on the timing of kidney failure beyond trial follow-up can assist informed decision-making by healthcare providers and patients. The study objective was therefore to extrapolate the outcome-based clinical benefits of treatment with dapagliflozin in patients with CKD via a time-to-event analysis using trial data. METHODS: Patient-level data from the DAPA-CKD trial were used to parameterize a closed cohort-level partitioned survival model that predicted time-to-event for key trial endpoints (kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure). Data were pooled with a subpopulation of the Dapagliflozin Effect on Cardiovascular Events - Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial to create a combined CKD population spanning a range of CKD stages; a parallel survival analysis was conducted in this population. RESULTS: In the DAPA-CKD and pooled CKD populations, treatment with dapagliflozin delayed time to first event for kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure. Attenuation of CKD progression was predicted to slow the time to kidney failure by 6.6 years [dapagliflozin: 25.2, 95% confidence interval (CI) 19.0-31.5; standard therapy: 18.5, 95% CI 14.7-23.4] in the DAPA-CKD population. A similar result was observed in the pooled CKD population with an estimated delay of 6.3 years (dapagliflozin: 36.0, 95% CI 31.9-38.3; standard therapy: 29.6, 95% CI 25.5-34.7). CONCLUSION: Treatment with dapagliflozin over a lifetime time horizon may considerably delay the mean time to adverse clinical outcomes for patients who would go on to experience them, including those at modest risk of progression.
引用
- McEwan P, Gabb PD, Davis JA, et al. The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis. Nephrol Dial Transplant. 2024. PMID: 38730538. doi:10.1093/ndt/gfae106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。